Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion

Acta Endocrinol (Copenh). 1993 Jan;128(1):9-14. doi: 10.1530/acta.0.1280009.

Abstract

Twenty-four hourly urinary growth hormone excretion (24-h uGH) has been quantified using a combination of ultrafiltration and conventional immunoradiometric assay. Twenty-four hourly uGH was measured in 20 normal adults and in 42 patients with acromegaly (9 untreated, 28 treated but with above-normal IGF-I levels, and 5 treated and cured). The means and ranges were as follows: 3.7 (1-9) ng/24 h for normals and 160 (40-540), 66 (2-380) and 5.2 (4-8) ng/24 h for the three groups of acromegalic patients, respectively. Ten patients with pituitary adenomas without acromegaly had 24-h uGH within the normal range. Twenty-four hourly uGH therefore gives a clear differentiation between controls and untreated patients. Log-transformed values for subjects with acromegaly showed significant correlations between 24-h uGH and levels of IGF-I (r = 0.63, p < 0.01), fasting plasma GH (r = 0.92, p < 0.001) and plasma GH after glucose loading (r = 0.85, p < 0.001). Twenty-four hourly uGH was also determined in three acromegalic patients before and during SMS 201-995 therapy. Twenty-four hourly uGH reflected the corresponding changes in mean levels for hourly sampling over 12 h of plasma GH and IGF-I and in clinical signs after 3-6 months of therapy. The results of this study indicate that 24-h uGH is an accurate indicator of GH secretion in acromegalic patients and could therefore be used both in diagnosis and in monitoring the progress of therapy in these patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acromegaly / blood
  • Acromegaly / diagnosis
  • Acromegaly / therapy
  • Acromegaly / urine*
  • Adenoma / urine
  • Adult
  • Aged
  • Circadian Rhythm
  • Female
  • Growth Hormone / blood
  • Growth Hormone / urine*
  • Humans
  • Immunoradiometric Assay
  • Insulin-Like Growth Factor I / analysis
  • Male
  • Middle Aged
  • Octreotide / therapeutic use
  • Pituitary Neoplasms / urine
  • Regression Analysis
  • Ultrafiltration

Substances

  • Insulin-Like Growth Factor I
  • Growth Hormone
  • Octreotide